Thomas Devlin, MD
Dr. Thomas Devlin has over 20 year experience as a vascular neurologist and is world-renowned for his research in ischemic stroke.
He served as the Chairman of the Neurology department for over 10 years at the University of Tennessee College of Medicine, where he is currently on faculty as a professor of neurology. He is the director of the CHI-Memorial Stroke & Neuroscience Center. He is also the owner and director of the Chattanooga Center for Neurologic Research (CCNR), where he has published numerous articles on acute stroke treatment and co-authored the first single center confirmation of the clinical benefit of advanced stroke thrombectomy procedures. His center was the highest enrolling in the SWIFT-PRIME study.
Previously, De. Devlin founded the non-profit Pleiades Foundation for Advanced Neuro-Medical Education, now maintained by Erlanger Health System, where he served as the Chairman of the Neurology Department.
Dr. Devlin currently services as the principal investigator for the DISTINCTION and LUMOSA trials. He helped to pioneer the use of a surgical devise for intracranial arterial dilation in acute stroke patients.
De. Devlin earned his medical degree from Baylor College of Medicine, completed his residency in neurology at Duke University and his fellowship in neurocritical care at the University of Virginia.
Financial relationships
-
Type of financial relationship:EmploymentIneligible company:Neuroscience Innovation FoundationDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Professional ServicesIneligible company:Nova SignalDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Professional ServicesIneligible company:Viz.aiDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Professional ServicesIneligible company:MedtronicDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Professional ServicesIneligible company:Speakers Bureau for Viz.aiDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Professional ServicesIneligible company:Board of Directors, Neuroscience Innovation FoundationDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:StockIneligible company:Viz.aiDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:StockIneligible company:Nova SignalDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Grant Or ContractIneligible company:Viz.aiDate added:03/30/2023Date updated:03/30/2023
-
Type of financial relationship:Grant Or ContractIneligible company:Nova SignalDate added:03/30/2023Date updated:03/30/2023